Evidence map›Paper›PMID 24729765›Full record

ArticleGastroenterology & hepatology2013

Gut bacteria in health and disease.

Eamonn M M Quigley

Open access · greenAbstract read
In one paragraph

Article in Gastroenterology & hepatology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 223 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
223citing papers in PubMed, 6 pooled it
6.3field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

223 citing papers in PubMed, 6 syntheses or guidelines pooled it, 327 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Probiotics for people with cystic fibrosis.The Cochrane database of systematic reviews · 2020
    Pooled it
  4. Pooled it
  5. Pooled it
  6. Systematic Review of the Effect of Enteral Feeding on Gut Microbiota in Preterm Infants.Journal of obstetric, gynecologic, and neonatal nursing : JOGNN · 2018
    Pooled it
  7. Trial
  8. Trial
  9. Review
  10. Proton pump inhibitor use is associated with increased complications compared to H2-receptor antagonists following multi-level lumbar fusion: a retrospective cohort study.European spine journal : official publication of the European Spine Society, the European Spinal Deformity Society, and the European Section of the Cervical Spine Research Society · 2026
    Article
  11. Review
  12. Review
  13. Article
  14. Structural and mechanistic diversity of glycogen phosphorylases from gut bacteria.Proceedings of the National Academy of Sciences of the United States of America · 2026
    Article
  15. Review
  16. Article
  17. Review
  18. Article
  19. Review
  20. Review

163 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author at 1 institution in 1 country.

Eamonn M M QuigleyDr Quigley is chief of the Division of Gastroenterology and Hepatology at Houston Methodist Hospital in Houston, Texas.
Methodist Hospital · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A new era in medical science has dawned with the realization of the critical role of the "forgotten organ," the gut micro-biota, in health and disease. Central to this beneficial interaction between the microbiota and host is the manner in which bacteria and most likely other microorganisms contained within the gut communicate with the host's immune system and participate in a variety of metabolic processes of mutual benefit to the host and the microbe. The advent of high-throughput methodologies and the elaboration of sophisticated analytic systems have facilitated the detailed description of the composition of the microbial constituents of the human gut, as never before, and are now enabling comparisons to be made between health and various disease states. Although the latter approach is still in its infancy, some important insights have already been gained about how the microbiota might influence a number of disease processes both within and distant from the gut. These discoveries also lay the groundwork for the development of therapeutic strategies that might modify the microbiota (eg, through the use of probiot-ics). Although this area holds much promise, more high-quality trials of probiotics, prebiotics, and other microbiota-modifying approaches in digestive disorders are needed, as well as laboratory investigations of their mechanisms of action.

Indexed as

gut bacteriaGut floramicrobial metabolismmicrobiotamucosal immunologyprobiotic

Identifiers

PMID24729765
PMCPMC3983973
OpenAlexW1557339302

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.